Clinical Report: What Holds Back MIGS

Overview

Surgeon reluctance to adopt minimally invasive glaucoma surgery (MIGS) may be influenced by cognitive biases that prioritize short-term risks over long-term benefits. Despite the safety and efficacy of MIGS, many cataract surgeons remain hesitant to incorporate these techniques into their practice.

Background

Minimally invasive glaucoma surgery (MIGS) has emerged as a promising option for managing glaucoma, particularly in conjunction with cataract surgery. However, adoption rates among surgeons remain low, which could impact patient outcomes. Understanding the psychological factors influencing surgical decision-making is crucial for improving MIGS uptake and ultimately enhancing patient care.

Data Highlights

No numerical data available in the source material.

Key Findings

• Surgeons may overemphasize short-term risks like hyphema while underestimating long-term benefits of MIGS.
• Hyphema, though rare, can significantly affect both patient and surgeon quality of life during its occurrence.
• Cognitive biases such as proximity bias and loss aversion contribute to surgeon hesitance in adopting MIGS.
• Interventional lasers and drug delivery methods may offer alternatives with fewer complications like hyphema.
• Patient acceptance of MIGS is high when offered during cataract surgery, yet many surgeons do not provide it.

Clinical Implications

Surgeons should be aware of cognitive biases that may hinder their decision-making regarding MIGS. By recognizing these biases, they can better evaluate the risks and benefits of MIGS, potentially leading to improved patient outcomes. Additionally, exploring alternative interventions may help mitigate concerns about complications.

Conclusion

Addressing cognitive biases and enhancing understanding of MIGS can facilitate broader adoption among surgeons, ultimately benefiting glaucoma patients. Continuous education and innovation in surgical techniques are essential for improving treatment outcomes.

References

1. Nathan M. Radcliffe, Glaucoma Physician, 2026 -- What Holds Back MIGS
2. New Retinal Physician, 2024 -- MIGS Device Market Growth Predicted
3. Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines, 2026
4. Six-Month Outcomes from a Prospective, Randomized Study of iStent infinite Versus Hydrus in Open-Angle Glaucoma, 2025
5. Efficacy and safety of trabeculectomy versus micro-invasive glaucoma procedures, 2026
6. New Retinal Physician — MIGS Device Market Growth Predicted Recommendations
7. Glaucoma Physician — Uptake of MIGS Among Glaucoma Specialists
8. Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines - Marta Pazos, Carlo E Traverso, Ananth Viswanathan, Augusto Azuara-Blanco, Luis Abegão Pinto, Ingeborg Stalmans, 2026
9. Six-Month Outcomes from a Prospective, Randomized Study of iStent infinite Versus Hydrus in Open-Angle Glaucoma: The INTEGRITY Study | Ophthalmology and Therapy | Springer Nature Link
10. Efficacy and safety of trabeculectomy versus micro-invasive glaucoma procedures (MIGPs) in managing glaucoma: a systematic review and meta-analysis | European Journal of Medical Research | Springer Nature Link
11. Outcomes of Minimally Invasive and Traditional Incisional Glaucoma Surgery: An IRIS® (Intelligent Research in Sight) Registry Study - ScienceDirect